125
Participants
Start Date
March 3, 2016
Primary Completion Date
April 13, 2017
Study Completion Date
April 13, 2017
DX-2930 - 300mg/2wk
300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
DX-2930 - 300mg/4wk
300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
DX-2930 - 150mg/4wk
150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
Placebo
Placebo administered every 2 weeks by subcutaneous injection.
The Mount Sinai Medical Center, New York
Charité - University of Berlin, Berlin
Winthrop University Hospital, Mineola
Triumpharma, Amman
Penn State Milton S. Hershey Medical Center, Hershey
Hospital L. Sacco, Milan University, Milan
Institute of Asthma & Allergy, P.C., Chevy Chase
Virginia Commonwealth University, Richmond
Duke Asthma, Allergy and Airway Center, Durham
American Health Research, Charlotte
University of South Florida, Tampa
Clinical Research Center of Alabama, LLC, Birmingham
Optimed Research, LTD, Columbus
Toledo Institute of Clinical Research, Toledo
Bernstein Clinical Research Center, LLC, Cincinnati
University of Michigan Hospital and Health System, Ann Arbor
Children's Hospital of Wisconsin, Milwaukee
Hautklinik und Poliklinik der Universitätsmedizin, Mainz
Midwest Immunology Clinic, Plymouth
Washington University School of Medicine, St Louis
HZRM Hamophilie-Zentrum Rhein Main, Mörfelden-Walldorf
University of Kansas Medical Center, Kansas City
AARA Research Center, Dallas
Austin Regional Clinic, Austin
IMMUNOe International Health & Research Centers, Centennial
Asthma and Allergy Associates, P.C., Colorado Springs
Intermountain Clinical Research, Draper
Allergy Associates of Utah, Murray
Medical Research of Arizona, Scottsdale
AIRE Medical of Los Angeles, Santa Monica
UC San Diego School of Medicine, San Diego
Allergy & Asthma Clinical Research, Walnut Creek
Marycliff Allergy Specialists, Spokane
Massachusetts General Hospital, Boston
Hudson-Essex Allergy, LLC, Belleville
Atlantic Research Center, LLC, Ocean City
Ottawa Allergy Research Corporation, Ottawa
Gordon Sussman Clinical Research Inc., Toronto
Clinique Specialisee en Allergie de la Capitale, Québec
Sociedad Alergologica, San Juan
Barts Health NHS Trust Clinical Research Centre, London
Lead Sponsor
Dyax Corp.
INDUSTRY
Shire
INDUSTRY